证券代码：002868 证券简称：绿康生化 公告编号：2023-070 绿康生化股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 绿康生化股份有限公司（以下简称"公司"）已于 2023 年 04 月 15 日在巨 潮资讯网上披露了《绿康生化股份有限公司 2022 年年度报告全文》及《绿康生 化股份有限公司 2022 年年度报告摘要》。为便于广大投资者更加全面深入地了 解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 12 日（星期五）15:00- 16:00 在"价值在线"（www.ir-online.cn）举办绿康生化股份有限公司 2022 年 二、参加人员 董事长、总经理 ：赖潭平 独立董事： 谭青 财务总监： 鲍忠寿 会议召开时间：2023 年 05 月 12 日（星期五）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集： 投 资 者 可 于 2023 年 05 月 12 日 前 访 问 网 址 h ...

证券代码：002868 证券简称：绿康生化 公告编号：2023-071 绿康生化股份有限公司 关于参加福建辖区上市公司 2023 年投资 者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，绿康生化股份有限公司（以下简 称"公 司"）将参加由福建证监局、福建省上市公司协会与深圳市全景网络有限公司联 合举办的"2023 年福建辖区上市公司投资者网上集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参 与本次互动交流，活动时间为 2023 年 5 月 15 日（周一） 16:00-17:30。届时 公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况和可 持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊 跃参与！ 特此公告！ 绿康生化股份有限公司 董事会 2023 年 05 月 09 日 ...

Revenue and Profitability - The company's revenue for Q1 2023 reached ¥100,190,694.85, representing a 59.83% increase compared to ¥62,687,107.78 in the same period last year[4] - The total revenue for Q1 2023 was approximately ¥134.54 million, representing a 72.80% increase compared to ¥77.86 million in the same period last year[15] - The net profit attributable to shareholders was -¥10,145,375.67, a decrease of 13.82% from -¥8,913,785.79 year-on-year[4] - The net profit for Q1 2023 was -10,416,863.97 CNY, compared to -9,003,935.49 CNY in Q1 2022, indicating a decline of approximately 15.7% year-over-year[27] - The company's gross profit was ¥-10,976,905.22, reflecting a decrease compared to the previous period's gross profit of ¥-7,675,193.16[25] - The total comprehensive income attributable to the parent company was -10,145,375.67 CNY, compared to -8,913,785.79 CNY in the same quarter last year[28] Cash Flow and Financial Position - Cash flow from operating activities showed a negative net amount of -¥61,917,676.50, a drastic decline from ¥5,001,432.08 in the same quarter last year, indicating a 1,338% decrease[4] - Cash flow from operating activities showed a net outflow of -61,917,676.50 CNY, a significant decrease from a net inflow of 5,001,432.08 CNY in Q1 2022[28] - The company experienced a net cash outflow from financing activities of -93,099,601.21 CNY, compared to a net inflow of 13,425,947.50 CNY in the previous year[29] - Cash and cash equivalents increased to ¥42,933,481.60 from ¥23,760,865.33, marking an increase of about 80.7%[22] - Cash received from tax refunds decreased by 54.12% to ¥10.92 million from ¥23.80 million due to a reduction in VAT refunds[15] - The cash received from bank loans increased by 56.83% to ¥122.43 million, reflecting the renewal of bank loans[15] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,176,564,201.90, down 5.11% from ¥1,239,862,406.54 at the end of the previous year[4] - The total assets at the end of the reporting period were ¥1,176,564,201.90, compared to ¥1,239,862,406.54 at the beginning of the year, a decrease of approximately 5.1%[24] - Total liabilities decreased to ¥587,680,408.76 from ¥640,561,749.43, a reduction of approximately 8.2%[24] - The company's equity attributable to shareholders decreased to ¥585,543,513.46 from ¥595,688,889.13, indicating a decline of about 1.9%[24] Inventory and Expenses - The company reported a significant increase in inventory, which rose by 84.53% to ¥164,340,165.06 from ¥89,060,779.22[9] - Total operating costs amounted to ¥111,167,600.07, up from ¥70,362,300.94, indicating an increase of about 58.0%[25] - Research and development expenses were ¥5,610,427.62, slightly down from ¥5,785,241.05, showing a decrease of about 3.0%[25] - The company experienced a 249.16% increase in financial expenses, amounting to ¥6,727,702.05, attributed to higher financing costs[12] - Cash paid for purchasing goods and services surged by 187.56% to ¥172.11 million, primarily due to the addition of the new subsidiary Jiangxi Weike[15] - The cash paid for taxes increased by 362.23% to ¥8.26 million from ¥1.79 million, attributed to tax payments from the new subsidiary Jiangxi Weike[15] Investments and Acquisitions - The investment income surged to ¥20,610,351.67, a 519.07% increase compared to a loss of -¥4,918,160.70 in the previous year, due to the sale of thermal power assets[12] - The company recorded a substantial increase in government subsidies, which rose by 286.74% to ¥4,189,281.45 from ¥1,083,242.05[12] - The company acquired 100% equity of Jiangxi Weike, resulting in cash payments of approximately ¥92.12 million[15] - The company’s goodwill increased to ¥65,966,311.97 following the acquisition of Jiangxi Weike, reflecting a 100% change as it was previously zero[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,545, with the largest shareholder holding 30.43% of the shares[17] - The basic and diluted earnings per share for Q1 2023 were both -0.07 CNY, compared to -0.06 CNY in Q1 2022[28] Audit Information - The company did not undergo an audit for the Q1 2023 report[31]

Financial Performance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[6]. - The company's operating revenue for 2022 was ¥329,850,238.49, a decrease of 9.23% compared to ¥363,386,382.24 in 2021[28]. - The net profit attributable to shareholders for 2022 was -¥121,938,109.79, representing a decline of 368.20% from -¥26,043,911.65 in 2021[28]. - The net cash flow from operating activities was -¥8,833,005.89 in 2022, a decrease of 125.11% compared to ¥35,170,418.50 in 2021[28]. - The total assets at the end of 2022 were ¥1,239,862,406.54, down 1.47% from ¥1,258,398,896.70 at the end of 2021[28]. - The basic earnings per share for 2022 was -¥0.79, a decrease of 364.71% from -¥0.17 in 2021[28]. - The weighted average return on net assets was -18.57% in 2022, down 15.04% from -3.53% in 2021[28]. - The company reported a significant increase in non-recurring losses, with a net profit after deducting non-recurring gains and losses of -¥123,209,841.64 in 2022, compared to -¥11,367,490.76 in 2021, a decline of 983.88%[28]. - The company reported a total profit of -CNY 134,110,321.30 and a net profit attributable to shareholders of -CNY 121,938,109.79, primarily due to high costs from new projects and market downturns[65]. Market and Industry Trends - The company is focused on expanding its market presence and developing new products and technologies, although specific figures are not provided in the available content[5]. - The veterinary medicine industry in China has seen a significant increase in production standards since the implementation of GMP regulations, leading to improved product quality and a favorable development environment for veterinary companies[42]. - In 2022, the top 20 pig farming companies accounted for 20%-25% of the total pig output and breeding stock, indicating a trend towards industry consolidation[44]. - The total pig output in China for 2022 was 699.95 million heads, representing a growth of 4.3% compared to the previous year[44]. - The global photovoltaic (PV) installed capacity reached 392.04 GW by the end of 2022, with a new installed capacity of 87.4 GW in China for the same year[46]. - The global demand for encapsulation films in the photovoltaic sector increased by 50% in 2022, reaching 2.7 billion square meters[48]. - The forecast for new PV installations in China for 2023 is between 95-120 GW, with global installations expected to reach 280-330 GW[46]. Strategic Initiatives - The company plans to acquire 100% equity of Jiangxi Weike New Materials Technology Co., Ltd., entering the photovoltaic film industry[41]. - The company plans to acquire 100% equity of Jiangxi Weike for cash, expanding into the photovoltaic film industry[68]. - The company is actively pursuing a dual-main business model of "animal protection products + photovoltaic film products" to ensure sustainable development[68]. - The company is focusing on developing green and safe veterinary drugs to meet future market demands[66]. - The company is currently developing new products, including L-tryptophan production technology, to enhance market competitiveness and increase sales[91]. - The company plans to invest a total of 6 billion RMB in the photovoltaic film project, which will add 100 production lines upon completion[114]. - The first phase of the project will complete 40 production lines within two years, with expected annual sales of 4 billion RMB upon reaching full capacity[115]. Governance and Compliance - The company has established a comprehensive governance structure and internal control system, ensuring compliance with relevant laws and regulations, and has conducted multiple shareholder meetings to uphold shareholder rights[127]. - The company has implemented a strict remuneration decision-making process based on its articles of association and relevant rules[152]. - The company has maintained effective internal control over financial reporting as of December 31, 2022, according to the internal control audit report[176]. - The company has established a commitment to not reduce its shareholding in the acquired shares through centralized bidding within 12 months of the transfer[194]. - The company has ensured compliance with all regulatory requirements regarding related party transactions[195]. Environmental and Social Responsibility - The company is subject to various environmental protection laws and has obtained necessary environmental permits for its operations[179]. - The company invested a total of 123.15 million yuan in environmental protection, including greening, pollution control, and environmental taxes in 2022[187]. - The company provided 40,000 yuan in support for poverty alleviation and rural revitalization efforts in 2022, specifically targeting impoverished villages[191]. - The company has engaged third-party operations for online monitoring of emissions and wastewater treatment to ensure compliance with environmental regulations[185]. - The company has committed to clean production practices and water conservation measures across all departments and workshops[187]. Research and Development - The company has accumulated significant technical reserves and customer resources, positioning itself as a major manufacturer of similar products globally, while actively exploring domestic and international markets[56]. - The company has obtained a total of 19 invention patents and 15 utility model patents, demonstrating its strong commitment to innovation and technology advancement in the production of veterinary drugs[59]. - The company's R&D investment decreased by 12.07% to ¥21,824,916.67 in 2022, accounting for 6.62% of operating revenue[92]. - The number of R&D personnel increased by 4.88% to 86 in 2022, with a slight decrease in the proportion of R&D staff to total employees from 11.19% to 10.91%[91]. Employee and Management Changes - The company experienced significant management changes, with multiple executives resigning for personal reasons, including the vice general managers and a board member[137]. - The current chairman and general manager is Mr. Lai Tanping, who has been in leadership roles since December 2009[139]. - The company has a total of 14 directors and supervisors, with varying remuneration amounts[153]. - The total number of employees at the end of the reporting period was 788, with 644 in the parent company and 144 in major subsidiaries[162].

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 2018-001 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 2019-001 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211230007 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211119003 | --- | --- | |---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211102001 | --- | --- | --- | |-------------------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...